What is Collegium Pharmaceutical Inc's earnings per share (EPS)?

Collegium Pharmaceutical Inc (COLL) reported diluted earnings per share of $1.73 for fiscal year 2025. This represents a -7.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Collegium Pharmaceutical Inc Financials

COLL

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Collegium Pharmaceutical Inc (COLL) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 57/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Collegium Pharmaceutical Inc has an operating margin of 23.0%, meaning the company retains $23 of operating profit per $100 of revenue. This strong profitability earns a score of 73/100, reflecting efficient cost management and pricing power. This is down from 26.9% the prior year.

Growth

Collegium Pharmaceutical Inc's revenue surged 23.6% year-over-year to $780.6M, reflecting rapid business expansion. This strong growth earns a score of 73/100.

Leverage

Collegium Pharmaceutical Inc has elevated debt relative to equity (D/E of 4.49), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 10/100, reflecting increased financial risk.

Liquidity

Collegium Pharmaceutical Inc's current ratio of 1.57 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 27/100, which could limit financial flexibility.

Cash Flow

100

Collegium Pharmaceutical Inc converts 42.0% of revenue into free cash flow ($327.6M). This strong cash generation earns a score of 100/100.

Returns

Collegium Pharmaceutical Inc's ROE of 20.8% shows moderate profitability relative to equity, earning a score of 57/100. This is down from 30.2% the prior year.

Altman Z-Score Distress

1.38

Collegium Pharmaceutical Inc scores 1.38, below the 1.81 distress threshold. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Piotroski F-Score Neutral

5/9

Collegium Pharmaceutical Inc passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Cash-Backed

5.24x

For every $1 of reported earnings, Collegium Pharmaceutical Inc generates $5.24 in operating cash flow ($329.3M OCF vs $62.9M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Adequate

2.2x

Collegium Pharmaceutical Inc earns $2.2 in operating income for every $1 of interest expense ($179.6M vs $82.3M). This adequate coverage means the company can meet its interest obligations, but has limited cushion if earnings fall.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$780.6M

YoY+23.6%

5Y CAGR+20.3%

Collegium Pharmaceutical Inc generated $780.6M in revenue in fiscal year 2025. This represents an increase of 23.6% from the prior year.

EBITDA

$405.7M

YoY+19.7%

5Y CAGR+28.1%

Collegium Pharmaceutical Inc's EBITDA was $405.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 19.7% from the prior year.

Net Income

$62.9M

YoY-9.1%

5Y CAGR+18.6%

Collegium Pharmaceutical Inc reported $62.9M in net income in fiscal year 2025. This represents a decrease of 9.1% from the prior year.

EPS (Diluted)

$1.73

YoY-7.0%

5Y CAGR+17.9%

Collegium Pharmaceutical Inc earned $1.73 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 7.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$327.6M

YoY+61.1%

5Y CAGR+30.0%

Collegium Pharmaceutical Inc generated $327.6M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 61.1% from the prior year.

Cash & Debt

$231.3M

YoY+227.7%

5Y CAGR+5.8%

10Y CAGR+9.2%

Collegium Pharmaceutical Inc held $231.3M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

32M

YoY+0.9%

5Y CAGR-1.8%

10Y CAGR+4.4%

Collegium Pharmaceutical Inc had 32M shares outstanding in fiscal year 2025. This represents an increase of 0.9% from the prior year.

Margins & Returns

Gross Margin

59.4%

YoY-0.4pp

5Y CAGR+1.3pp

Collegium Pharmaceutical Inc's gross margin was 59.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 0.4 percentage points from the prior year.

Operating Margin

23.0%

YoY-3.9pp

5Y CAGR+4.9pp

Collegium Pharmaceutical Inc's operating margin was 23.0% in fiscal year 2025, reflecting core business profitability. This is down 3.9 percentage points from the prior year.

Net Margin

8.1%

YoY-2.9pp

5Y CAGR-0.6pp

Collegium Pharmaceutical Inc's net profit margin was 8.1% in fiscal year 2025, showing the share of revenue converted to profit. This is down 2.9 percentage points from the prior year.

Return on Equity

20.8%

YoY-9.4pp

5Y CAGR+6.5pp

10Y CAGR+52.9pp

Collegium Pharmaceutical Inc's ROE was 20.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 9.4 percentage points from the prior year.

Capital Allocation

R&D Spending

N/A

Share Buybacks

$25.1M

YoY-58.2%

Collegium Pharmaceutical Inc spent $25.1M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 58.2% from the prior year.

Capital Expenditures

$1.7M

YoY+5.3%

5Y CAGR-20.7%

10Y CAGR+17.0%

Collegium Pharmaceutical Inc invested $1.7M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 5.3% from the prior year.

COLL Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$780.6M+23.6%	$631.4M+11.4%	$566.8M+22.2%	$463.9M+67.6%	$276.9M-10.7%	$310.0M
Cost of Revenue	$317.3M+24.9%	$254.1M+5.6%	$240.6M-5.4%	$254.4M+101.5%	$126.3M-3.0%	$130.2M
Gross Profit	$463.3M+22.8%	$377.3M+15.7%	$326.2M+55.7%	$209.5M+39.1%	$150.6M-16.2%	$179.8M
R&D Expenses	N/A	$0	$0-100.0%	$4.0M-57.9%	$9.5M-3.3%	$9.8M
SG&A Expenses	$284.8M+35.4%	$210.4M+32.1%	$159.2M-7.5%	$172.2M+44.7%	$119.0M+4.5%	$113.8M
Operating Income	$179.6M+5.7%	$169.9M+1.8%	$167.0M+401.1%	$33.3M+89.0%	$17.6M-68.7%	$56.2M
Interest Expense	$82.3M+11.3%	$74.0M-11.2%	$83.3M+31.8%	$63.2M+200.8%	$21.0M-27.2%	$28.9M
Income Tax	$29.7M+1.3%	$29.4M+6.5%	$27.6M+817.2%	-$3.8M+94.9%	-$74.9M-9123.0%	$830K
Net Income	$62.9M-9.1%	$69.2M+43.7%	$48.2M+292.6%	-$25.0M-135.0%	$71.5M+167.3%	$26.8M
EPS (Diluted)	$1.73-7.0%	$1.86+44.2%	$1.29+274.3%	$-0.74-139.8%	$1.86+144.7%	$0.76

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$205.4M-1.9%	$209.4M+11.4%	$188.0M+5.8%	$177.8M-2.3%	$181.9M+14.2%	$159.3M+9.7%	$145.3M+0.2%	$144.9M
Cost of Revenue	$77.1M-3.9%	$80.2M+0.7%	$79.6M-1.0%	$80.4M-3.9%	$83.7M+33.8%	$62.5M+14.8%	$54.5M+1.9%	$53.5M
Gross Profit	$128.4M-0.6%	$129.2M+19.2%	$108.4M+11.4%	$97.3M-1.0%	$98.3M+1.5%	$96.8M+6.6%	$90.8M-0.7%	$91.5M
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$67.6M+0.8%	$67.1M-8.9%	$73.6M-3.6%	$76.4M+21.1%	$63.1M+1.8%	$62.0M+43.0%	$43.3M+3.2%	$42.0M
Operating Income	$60.8M-2.1%	$62.1M+76.9%	$35.1M+61.9%	$21.7M-43.1%	$38.1M+9.4%	$34.8M-26.6%	$47.5M-4.0%	$49.5M
Interest Expense	$19.3M-11.4%	$21.8M+6.4%	$20.5M-1.6%	$20.8M-8.2%	$22.7M+23.2%	$18.4M+18.0%	$15.6M-10.1%	$17.3M
Income Tax	$12.1M+1.2%	$11.9M+136.6%	$5.0M+615.2%	$705K-85.1%	$4.7M-24.2%	$6.2M-34.2%	$9.5M+6.5%	$8.9M
Net Income	$17.0M-46.2%	$31.5M+162.9%	$12.0M+395.8%	$2.4M-80.7%	$12.5M+34.3%	$9.3M-52.4%	$19.6M-29.3%	$27.7M
EPS (Diluted)	$0.46-45.2%	$0.84+147.1%	$0.34+385.7%	$0.07-80.6%	$0.36+33.3%	$0.27-48.1%	$0.52-26.8%	$0.71

COLL Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$1.7B-0.4%	$1.7B+45.5%	$1.1B-2.6%	$1.2B+69.7%	$692.1M+7.5%	$643.8M
Current Assets	$691.4M+43.4%	$482.3M-10.3%	$537.6M+28.0%	$420.0M+33.1%	$315.5M+13.6%	$277.9M
Cash & Equivalents	$231.3M+227.7%	$70.6M-70.5%	$238.9M+37.6%	$173.7M-6.8%	$186.4M+7.1%	$174.1M
Inventory	$40.9M+15.1%	$35.6M+10.0%	$32.3M-30.5%	$46.5M+167.3%	$17.4M+11.4%	$15.6M
Accounts Receivable	$211.3M-7.5%	$228.5M+27.3%	$179.5M-2.0%	$183.1M+73.0%	$105.8M+27.0%	$83.3M
Goodwill	$145.9M-10.1%	$162.3M+21.3%	$133.9M+0.1%	$133.7M	N/A	N/A
Total Liabilities	$1.4B-5.5%	$1.4B+51.4%	$947.9M-3.2%	$979.3M+100.2%	$489.1M+6.8%	$457.8M
Current Liabilities	$440.0M-13.6%	$509.5M+11.3%	$457.9M+5.6%	$433.7M+55.1%	$279.6M+16.8%	$239.5M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$301.7M+31.8%	$228.8M+17.1%	$195.4M+0.3%	$194.8M-4.0%	$202.9M+9.1%	$186.0M
Retained Earnings	-$101.1M+38.3%	-$164.0M+29.7%	-$233.2M+17.1%	-$281.3M-9.8%	-$256.3M+23.1%	-$333.1M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$1.7B+3.1%	$1.6B+0.9%	$1.6B-2.4%	$1.6B-1.9%	$1.7B+1.7%	$1.6B+55.2%	$1.1B-5.5%	$1.1B
Current Assets	$691.4M+12.6%	$613.9M+11.8%	$549.2M+4.1%	$527.6M+9.4%	$482.3M+8.7%	$443.8M-13.0%	$510.2M-5.4%	$539.3M
Cash & Equivalents	$231.3M+54.1%	$150.1M+27.9%	$117.3M+22.0%	$96.2M+36.3%	$70.6M+81.1%	$39.0M-77.5%	$172.9M-24.4%	$228.6M
Inventory	$40.9M+7.5%	$38.1M-0.3%	$38.1M+2.5%	$37.2M+4.7%	$35.6M-6.5%	$38.0M+36.5%	$27.9M-10.9%	$31.3M
Accounts Receivable	$211.3M-9.7%	$233.9M+9.8%	$213.0M-6.9%	$228.7M+0.1%	$228.5M0.0%	$228.5M+24.3%	$183.9M+5.2%	$174.7M
Goodwill	$145.9M0.0%	$145.9M-1.4%	$147.9M-1.9%	$150.8M-7.1%	$162.3M+11.2%	$146.0M+9.0%	$133.9M0.0%	$133.9M
Total Liabilities	$1.4B+1.7%	$1.3B-2.1%	$1.4B-2.6%	$1.4B-2.6%	$1.4B+2.4%	$1.4B+67.4%	$836.8M-6.2%	$892.1M
Current Liabilities	$440.0M-2.8%	$452.9M-2.5%	$464.6M-4.5%	$486.7M-4.5%	$509.5M+10.9%	$459.4M-0.5%	$461.7M+3.4%	$446.4M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$301.7M+9.8%	$274.8M+18.3%	$232.2M-1.0%	$234.4M+2.4%	$228.8M-2.3%	$234.3M+8.2%	$216.6M-2.5%	$222.2M
Retained Earnings	-$101.1M+14.4%	-$118.1M+21.1%	-$149.6M+7.4%	-$161.6M+1.5%	-$164.0M+7.1%	-$176.5M+5.0%	-$185.9M+9.5%	-$205.5M

COLL Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$329.3M+60.7%	$205.0M-25.4%	$274.7M+121.2%	$124.2M+20.0%	$103.6M+10.2%	$93.9M
Capital Expenditures	$1.7M+5.3%	$1.7M+258.4%	$461K-71.6%	$1.6M-16.6%	$1.9M-64.9%	$5.5M
Free Cash Flow	$327.6M+61.1%	$203.3M-25.9%	$274.3M+123.7%	$122.6M+20.7%	$101.6M+15.0%	$88.4M
Investing Cash Flow	-$63.5M+77.9%	-$287.8M-306.4%	-$70.8M+87.7%	-$573.7M-29410.9%	-$1.9M+99.5%	-$373.8M
Financing Cash Flow	-$110.2M-81.9%	-$60.6M+56.8%	-$140.2M-132.1%	$436.7M+589.0%	-$89.3M-131.2%	$286.5M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$25.1M-58.2%	$60.0M-20.0%	$75.0M+433.3%	$14.1M-70.6%	$47.9M	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	$123.0M+56.9%	$78.4M+8.3%	$72.4M+30.8%	$55.4M-34.6%	$84.6M+1040.6%	-$9.0M-113.4%	$67.4M+8.8%	$61.9M
Capital Expenditures	$689K+266.5%	$188K+189.2%	$65K-91.9%	$798K+40.0%	$570K+133.6%	$244K-9.6%	$270K-52.5%	$568K
Free Cash Flow	$122.4M+56.4%	$78.3M+8.1%	$72.4M+32.6%	$54.6M-35.1%	$84.1M+1009.6%	-$9.2M-113.8%	$67.1M+9.4%	$61.4M
Investing Cash Flow	-$20.1M+35.0%	-$30.9M-958.9%	-$2.9M+69.9%	-$9.7M+17.7%	-$11.8M+95.3%	-$249.0M-2695.5%	-$8.9M+50.9%	-$18.1M
Financing Cash Flow	-$21.8M-47.3%	-$14.8M+69.4%	-$48.4M-91.7%	-$25.2M+38.9%	-$41.3M-127.7%	$149.0M+230.5%	-$114.2M-110.9%	-$54.1M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$0	$0	N/A	N/A	$25.0M	$0	N/A	N/A

COLL Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	59.4%-0.4pp	59.8%+2.2pp	57.6%+12.4pp	45.1%-9.3pp	54.4%-3.6pp	58.0%
Operating Margin	23.0%-3.9pp	26.9%-2.5pp	29.5%+22.3pp	7.2%+0.8pp	6.4%-11.8pp	18.1%
Net Margin	8.1%-2.9pp	11.0%+2.5pp	8.5%+13.9pp	-5.4%-31.2pp	25.8%+17.2pp	8.6%
Return on Equity	20.8%-9.4pp	30.2%+5.6pp	24.6%+37.5pp	-12.8%-48.1pp	35.2%+20.9pp	14.4%
Return on Assets	3.8%-0.4pp	4.2%-0.1pp	4.2%+6.3pp	-2.1%-12.5pp	10.3%+6.2pp	4.2%
Current Ratio	1.57+0.6	0.95-0.2	1.17+0.2	0.97-0.2	1.13-0.0	1.16
Debt-to-Equity	4.49-1.8	6.27+1.4	4.85-0.2	5.03+2.6	2.41-0.1	2.46
FCF Margin	42.0%+9.8pp	32.2%-16.2pp	48.4%+22.0pp	26.4%-10.3pp	36.7%+8.2pp	28.5%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	62.5%+0.8pp	61.7%+4.0pp	57.6%+2.9pp	54.8%+0.7pp	54.0%-6.7pp	60.8%-1.7pp	62.5%-0.6pp	63.1%
Operating Margin	29.6%-0.1pp	29.7%+11.0pp	18.7%+6.5pp	12.2%-8.8pp	20.9%-0.9pp	21.9%-10.8pp	32.7%-1.5pp	34.1%
Net Margin	8.3%-6.8pp	15.0%+8.7pp	6.4%+5.0pp	1.4%-5.5pp	6.9%+1.0pp	5.9%-7.6pp	13.5%-5.6pp	19.1%
Return on Equity	5.6%-5.8pp	11.5%+6.3pp	5.2%+4.1pp	1.0%-4.5pp	5.5%+1.5pp	4.0%-5.1pp	9.0%-3.4pp	12.5%
Return on Assets	1.0%-0.9pp	2.0%+1.2pp	0.8%+0.6pp	0.1%-0.6pp	0.8%+0.2pp	0.6%-1.3pp	1.9%-0.6pp	2.5%
Current Ratio	1.57+0.2	1.36+0.2	1.18+0.1	1.08+0.1	0.95-0.0	0.97-0.1	1.10-0.1	1.21
Debt-to-Equity	4.49-0.4	4.85-1.0	5.86-0.1	5.96-0.3	6.27+0.3	5.98+2.1	3.86-0.2	4.02
FCF Margin	59.6%+22.2pp	37.4%-1.1pp	38.5%+7.8pp	30.7%-15.5pp	46.2%+52.0pp	-5.8%-52.0pp	46.2%+3.9pp	42.4%

Similar Companies

Pacira Biosciences Inc PCRX

$919.1M

Dynavax Technolo DVAX

$1.8B

Harrow Health Inc HROW

$1.3B

Amphastar Pharma AMPH

$927.8M

Evotec Ag EVO

$920.7M

Frequently Asked Questions

What is Collegium Pharmaceutical Inc's annual revenue?

Collegium Pharmaceutical Inc (COLL) reported $780.6M in total revenue for fiscal year 2025. This represents a 23.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Collegium Pharmaceutical Inc's revenue growing?

Collegium Pharmaceutical Inc (COLL) revenue grew by 23.6% year-over-year, from $631.4M to $780.6M in fiscal year 2025.

Is Collegium Pharmaceutical Inc profitable?

Yes, Collegium Pharmaceutical Inc (COLL) reported a net income of $62.9M in fiscal year 2025, with a net profit margin of 8.1%.

What is Collegium Pharmaceutical Inc's EBITDA?

Collegium Pharmaceutical Inc (COLL) had EBITDA of $405.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Collegium Pharmaceutical Inc's gross margin?

Collegium Pharmaceutical Inc (COLL) had a gross margin of 59.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Collegium Pharmaceutical Inc's operating margin?

Collegium Pharmaceutical Inc (COLL) had an operating margin of 23.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Collegium Pharmaceutical Inc's net profit margin?

Collegium Pharmaceutical Inc (COLL) had a net profit margin of 8.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Collegium Pharmaceutical Inc's return on equity (ROE)?

Collegium Pharmaceutical Inc (COLL) has a return on equity of 20.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Collegium Pharmaceutical Inc's free cash flow?

Collegium Pharmaceutical Inc (COLL) generated $327.6M in free cash flow during fiscal year 2025. This represents a 61.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Collegium Pharmaceutical Inc's operating cash flow?

Collegium Pharmaceutical Inc (COLL) generated $329.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Collegium Pharmaceutical Inc's total assets?

Collegium Pharmaceutical Inc (COLL) had $1.7B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Collegium Pharmaceutical Inc's capital expenditures?

Collegium Pharmaceutical Inc (COLL) invested $1.7M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Does Collegium Pharmaceutical Inc buy back shares?

Yes, Collegium Pharmaceutical Inc (COLL) spent $25.1M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Collegium Pharmaceutical Inc have outstanding?

Collegium Pharmaceutical Inc (COLL) had 32M shares outstanding as of fiscal year 2025.

What is Collegium Pharmaceutical Inc's current ratio?

Collegium Pharmaceutical Inc (COLL) had a current ratio of 1.57 as of fiscal year 2025, which is generally considered healthy.

What is Collegium Pharmaceutical Inc's debt-to-equity ratio?

Collegium Pharmaceutical Inc (COLL) had a debt-to-equity ratio of 4.49 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Collegium Pharmaceutical Inc's return on assets (ROA)?

Collegium Pharmaceutical Inc (COLL) had a return on assets of 3.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Collegium Pharmaceutical Inc's Altman Z-Score?

Collegium Pharmaceutical Inc (COLL) has an Altman Z-Score of 1.38, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Collegium Pharmaceutical Inc's Piotroski F-Score?

Collegium Pharmaceutical Inc (COLL) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Collegium Pharmaceutical Inc's earnings high quality?

Collegium Pharmaceutical Inc (COLL) has an earnings quality ratio of 5.24x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Collegium Pharmaceutical Inc cover its interest payments?

Collegium Pharmaceutical Inc (COLL) has an interest coverage ratio of 2.2x, meaning it can adequately cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Collegium Pharmaceutical Inc?

Collegium Pharmaceutical Inc (COLL) scores 57 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.